| Literature DB >> 35736967 |
Nguyen Vu Trung1,2, Le Thi Hoi1, Tran Mai Hoa1, Dang Thi Huong1, Ma Thi Huyen1, Vuong Quang Tien1, Dao Thi Tuyet Mai1, Nguyen Thi Thu Ha3, Nguyen Van Kinh4, Christina M Farris5, Allen L Richards5,6.
Abstract
In Vietnam, the public health burden of rickettsial infections continues to be underestimated due to knowledge gaps in the epidemiology of these diseases. We conducted a systematic study among 27 hospitals from 26 provinces in eight ecological regions throughout Vietnam to investigate the prevalence, distribution, and clinical characteristics of rickettsial diseases. We recruited 1834 patients in the study from April 2018 to October 2019. The findings showed that rickettsial diseases were common among undifferentiated febrile patients, with 564 (30.8%) patients positive by qPCR for scrub typhus, murine typhus or spotted fever. Scrub typhus (484, 85.8%) was the most common rickettsial disease, followed by murine typhus (67, 11.9%) and spotted fever (10, 1.8%). Rickettsial diseases were widely distributed in all regions of Vietnam and presented with nonspecific clinical manifestations.Entities:
Keywords: epidemiology; hospital surveillance; murine typhus; rickettsial diseases; scrub typhus; spotted fever rickettsioses
Year: 2022 PMID: 35736967 PMCID: PMC9231031 DOI: 10.3390/tropicalmed7060088
Source DB: PubMed Journal: Trop Med Infect Dis ISSN: 2414-6366
Figure 1Enrollment flow of the study.
General characteristics of patients enrolled in the study.
| Characteristics | Total | qPCR Negative | qPCR Positive | ||
|---|---|---|---|---|---|
|
| |||||
| Age ( | 39 (27–55) | 38 (27–54) | 42 (24–58) | 0.2883 ‡ | |
|
| |||||
| Sex ( | Female | 861 (47.0) | 554 (44.1) | 307 (53.4) |
|
| Male | 970 (53.0) | 702 (55.9) | 268 (46.6) | ||
| Residence ( | Rural area | 1271 (69.4) | 813 (64.8) | 458 (79.2) |
|
| Urban area | 561 (30.6) | 441 (35.2) | 120 (20.8) | ||
| Occupation | Farmer | 866 (47.2) | 550 (43.8) | 316 (54.7) |
|
| Non-farmer | 968 (52.8) | 706 (56.2) | 262 (45.3) | ||
| Origin ( | Admitted from community | 1175 (64.1) | 858 (68.3) | 317 (54.8) |
|
| Transferred from another hospital or clinic | 659 (35.9) | 398 (31.7) | 261 (45.2) | ||
| Used antimicrobial drugs before admission ( | Yes | 426 (23.2) | 264 (21.0) | 162 (28.0) |
|
| No | 1408 (76.8) | 992 (79.0) | 416 (72.0) | ||
† p value obtained using Fisher exact test, except where noted. ‡ p value obtained using Mann-Whitney test.
Figure 2Frequency and Distribution of Enrolled Patients. (a) The number of patients that participated in the study by province of hospital. (b) The number of patients by province of residence. The color corresponds to patient distribution with the darker the color, the higher the number of enrollees.
Figure 3qPCR results for scrub typhus, murine typhus and spotted fever among 1834 febrile patients in the study.
Figure 4Distribution of confirmed cases of: (a) Scrub Typhus, n = 484; (b) Murine Typhus, n = 67; and (c) Spotted Fever, n = 10 (c) by provinces. The color density corresponds to the number of confirmed cases: the darker the color, the higher the number of confirmed cases. The fraction shows the number of confirmed case (numerator) and the number of recruited patients (denominator) for each province.
Figure 5Frequency of Patients with Confirmed Scrub Typhus, Murine Typhus and Spotted Fever in the North and the South of Vietnam by Month.
Demographics, history, clinical manifestations, laboratory results, treatment, and outcomes of 484 scrub typhus, 67 murine typhus and 10 spotted fever patients.
| Characteristics | Scrub Typhus | Murine Typhus | Spotted Fever | Total | |
|---|---|---|---|---|---|
|
| |||||
| Age, median (IQR) ( | 43 (24–58) | 43 (31–54) | 28 (18–37) | 42.5 (24–58) | 0.344 ¶ |
| Male, ( | 206 (42.6) | 42 (63.6) | 8 (80.0) | 256 (45.7) |
|
| Female ( | 278 (57.4) | 24 (36.4) | 2 (20.0) | 304 (54.3) | |
| Farmer, | 283 (58.5) | 18 (26.9) | 5 (50.0) | 306 (54.6) |
|
| Residence in rural area, | 402 (83.1) | 36 (53.7) | 6 (60.0) | 444 (79.1) |
|
|
| |||||
| Admitted from community, | 264 (54.5) | 37 (55.2) | 5 (50.0) | 398 (54.6) | 1.000 |
| Transferred from other hospital or clinic, | 220 (45.6) | 30 (44.8) | 5 (50.0) | 255 (45.4) | |
| Received antimicrobial drugs before admission, | 135 (27.9) | 20 (29.9) | 3 (30.0) | 158 (28.2) | 0.772 |
|
| |||||
| Headache, | 448 (92.6) | 62 (92.5) | 10 (100) | 520 (92.7) | 1.000 |
| Myalgia, | 250 (51.7) | 44 (65.7) | 9 (90.0) | 303 (54.0) |
|
| Retro-orbital pain, | 105 (21.7) | 21 (31.3) | 2 (20.0) | 128 (22.9) | 0.088 |
| Sore throat, | 117 (24.2) | 24 (35.8) | 3 (30.0) | 144 (25.7) | 0.098 |
| Cough, | 220 (45.6) | 34 (50.8) | 5 (50.0) | 259 (46.3) | 0.435 |
| Nausea, | 147 (30.4) | 23 (34.3) | 4 (40.0) | 174 (31.0) | 0.573 |
| Vomiting, | 72 (14.9) | 11 (16.4) | 0 | 83 (14.8) | 0.717 |
| Abdominal pain, | 95 (19.6) | 7 (10.5) | 0 | 102 (18.2) | 0.092 |
| Diarrhea, | 59 (12.2) | 6 (9.0) | 0 | 65 (11.6) | 0.547 |
| Skin hyperemia, | 124 (25.7) | 27 (40.3) | 0 | 151 (27.0) |
|
|
| |||||
| Congested skin, | 273 (56.4) | 54 (80.6) | 4 (40.0) | 331 (59.0) |
|
| Conjunctivitis, | 163 (33.7) | 36 (53.7) | 3 (10.0) | 202 (36.0) |
|
| Eschar, | 368 (76.0) | 4 (6.0) | 1 (10.0) | 373 (66.5) |
|
| Rash, | 118 (24.4) | 26 (38.8) | 0 | 144 (25.7) |
|
| Lymphadenopathy, | 243 (50.2) | 7 (10.5) | 1 (10.0) | 251 (44.7) |
|
| Liver enlargement, | 28 (5.8) | 0 | 2 (20.0) | 30 (5.4) |
|
| Spleen enlargement, | 31 (6.4) | 0 | 1 (10.0) | 32 (5.7) |
|
| Subcutaneous hemorrhage, | 13 (2.7) | 5 (7.5) | 0 | 18 (3.2) | 0.056 |
| Mucous membrane hemorrhage, | 5 (1.0) | 2 (3.0) | 0 | 7 (1.3) | 0.205 |
| Rales, | 64 (13.2) | 8 (11.9) | 0 | 72 (12.8) | 1.000 |
|
| |||||
| Erythrocytes, T/L, median (IQR), | 4.4 (3.9–4.7) | 4.5 (4.2–4.9) | 4.4 (4.1–4.8) | 4.4 (4.0–4.7) |
|
| Leukocytes, T/L, median (IQR), | 7.5 (5.6–10.3) | 6.5 (5.0–8.7) | 6.2 (4.2–7.7) | 7.4 (5.5–10.0) |
|
| Platelets, G/L, median (IQR), | 100 (66–144) | 87.5 (65–133) | 177.5 (75–269.5) | 100 (66–144) | 0.303 ¶ |
| Platelet < 100 G/L, | 187 (51.5) | 20 (45.5) | 6 (75.0) | 213 (51.3) | 0.524 |
| Alanine aminotransferase > 40 IU/L, | 282 (85.2) | 36 (97.3) | 7 (87.5) | 325 (86.4) |
|
| Aspartate aminotransferase ST > 37 IU/L, | 316 (95.8) | 35 (94.6) | 8 (100) | 359 (95.7) | 0.670 |
| Total bilirubin > 17 µmol/L, | 18 (23.4) | 2 (18.2) | 0 | 20 (24.4) | 1.000 |
| Albumin < 32 g/L, | 54 (54.6) | 1 (8.3) | 0 | 55 (49.6) |
|
| Creatinine > 120 µmol/L, | 19 (6.1) | 1 (3.0) | 0 | 20 (5.7) | 0.706 |
|
| |||||
| One of three protocol-specific antibiotics (Doxycycline, Chloramphenicol and Azithromycin), | 478 (98.8) | 62 (92.5) | 8 (80.0) | 548 (97.7) | - |
| Non-protocol antibiotics, | 4 (0.8) | 4 (6.0) | 1 (10.0) | 9 (1.6) | |
| Other therapies, ( | 2 (0.4) | 1 (1.5) | 1 (10.0) | 4 (0.7) | |
| Respiratory support, | 31 (6.4) | 4 (6.0) | 0 | 35 (6.2) | 1.000 |
| Albumin transfusion, | 23 (4.8) | 3 (4.6) | 0 | 26 (4.7) | 1.000 |
| Blood purification, | 3 (0.6) | 0 | 0 | 3 (0.5) | 1.000 |
|
| |||||
| Death, | 5 (1.0) | 1 (1.5) | 0 | 6 (1.1) | 0.542 |
| No. days in hospital, | 6 (5–8) | 7 (5–8) | 7 (5–7) | 6 (5–8) | 0.128 ¶ |
| Suffering from shock, | 6 (1.2) | 1 (1.5) | 0 | 7 (1.3) | 0.595 |
| Afebrile ≤ 72 h after treatment began, | 418 (88.2) | 47 (77.1) | 9 (90.0) | 474 (87.0) |
|
§p value obtained when comparing between scrub and murine typhus groups, using Fisher’s exact test, except where noted. ¶ p value obtained when comparing between scrub and murine typhus groups using Mann-Whitney test.